241 related articles for article (PubMed ID: 37979169)
1. Evolution of the SARS-CoV-2 Omicron spike.
Parsons RJ; Acharya P
Cell Rep; 2023 Dec; 42(12):113444. PubMed ID: 37979169
[TBL] [Abstract][Full Text] [Related]
2. Evolution of Immune Evasion and Host Range Expansion by the SARS-CoV-2 B.1.1.529 (Omicron) Variant.
Ren W; Zhang Y; Rao J; Wang Z; Lan J; Liu K; Zhang X; Hu X; Yang C; Zhong G; Zhang R; Wang X; Shan C; Ding Q
mBio; 2023 Apr; 14(2):e0041623. PubMed ID: 37010428
[TBL] [Abstract][Full Text] [Related]
3. Unique mutations in SARS-CoV-2 Omicron subvariants' non-spike proteins: Potential impacts on viral pathogenesis and host immune evasion.
Hossain A; Akter S; Rashid AA; Khair S; Alam ASMRU
Microb Pathog; 2022 Sep; 170():105699. PubMed ID: 35944840
[TBL] [Abstract][Full Text] [Related]
4. In Silico Genome Analysis Reveals the Evolution and Potential Impact of SARS-CoV-2 Omicron Structural Changes on Host Immune Evasion and Antiviral Therapeutics.
Chauhan D; Chakravarty N; Jeyachandran AV; Jayakarunakaran A; Sinha S; Mishra R; Arumugaswami V; Ramaiah A
Viruses; 2022 Nov; 14(11):. PubMed ID: 36366559
[TBL] [Abstract][Full Text] [Related]
5. Differentiating Cell Entry Potentials of SARS-CoV-2 Omicron Subvariants on Human Lung Epithelium Cells.
Katte RH; Ao Y; Xu W; Han Y; Zhong G; Ghimire D; Florence J; Tucker TA; Lu M
Viruses; 2024 Mar; 16(3):. PubMed ID: 38543757
[TBL] [Abstract][Full Text] [Related]
6. Adaptive variations in SARS-CoV-2 spike proteins: effects on distinct virus-cell entry stages.
Qing E; Gallagher T
mBio; 2023 Aug; 14(4):e0017123. PubMed ID: 37382441
[TBL] [Abstract][Full Text] [Related]
7. The Biological Functions and Clinical Significance of SARS-CoV-2 Variants of Corcern.
Akkız H
Front Med (Lausanne); 2022; 9():849217. PubMed ID: 35669924
[TBL] [Abstract][Full Text] [Related]
8. The Increased Amyloidogenicity of Spike RBD and pH-Dependent Binding to ACE2 May Contribute to the Transmissibility and Pathogenic Properties of SARS-CoV-2 Omicron as Suggested by In Silico Study.
Aksenova AY; Likhachev IV; Grishin SY; Galzitskaya OV
Int J Mol Sci; 2022 Nov; 23(21):. PubMed ID: 36362302
[TBL] [Abstract][Full Text] [Related]
9. Sensitivity to Vaccines, Therapeutic Antibodies, and Viral Entry Inhibitors and Advances To Counter the SARS-CoV-2 Omicron Variant.
Zhou H; Møhlenberg M; Thakor JC; Tuli HS; Wang P; Assaraf YG; Dhama K; Jiang S
Clin Microbiol Rev; 2022 Sep; 35(3):e0001422. PubMed ID: 35862736
[TBL] [Abstract][Full Text] [Related]
10. Immune evasion of neutralizing antibodies by SARS-CoV-2 Omicron.
Wang L; Møhlenberg M; Wang P; Zhou H
Cytokine Growth Factor Rev; 2023 Apr; 70():13-25. PubMed ID: 36948931
[TBL] [Abstract][Full Text] [Related]
11. Structural Basis for the Enhanced Infectivity and Immune Evasion of Omicron Subvariants.
Li Y; Shen Y; Zhang Y; Yan R
Viruses; 2023 Jun; 15(6):. PubMed ID: 37376697
[TBL] [Abstract][Full Text] [Related]
12. Characterization of Entry Pathways, Species-Specific Angiotensin-Converting Enzyme 2 Residues Determining Entry, and Antibody Neutralization Evasion of Omicron BA.1, BA.1.1, BA.2, and BA.3 Variants.
Neerukonda SN; Wang R; Vassell R; Baha H; Lusvarghi S; Liu S; Wang T; Weiss CD; Wang W
J Virol; 2022 Sep; 96(17):e0114022. PubMed ID: 36000843
[TBL] [Abstract][Full Text] [Related]
13. Omicron: What Makes the Latest SARS-CoV-2 Variant of Concern So Concerning?
Jung C; Kmiec D; Koepke L; Zech F; Jacob T; Sparrer KMJ; Kirchhoff F
J Virol; 2022 Mar; 96(6):e0207721. PubMed ID: 35225672
[TBL] [Abstract][Full Text] [Related]
14. Characterization of SARS-CoV-2 Variants B.1.617.1 (Kappa), B.1.617.2 (Delta), and B.1.618 by Cell Entry and Immune Evasion.
Ren W; Ju X; Gong M; Lan J; Yu Y; Long Q; Kenney DJ; O'Connell AK; Zhang Y; Zhong J; Zhong G; Douam F; Wang X; Huang A; Zhang R; Ding Q
mBio; 2022 Apr; 13(2):e0009922. PubMed ID: 35266815
[TBL] [Abstract][Full Text] [Related]
15. Omicron variant (B.1.1.529) and its sublineages: What do we know so far amid the emergence of recombinant variants of SARS-CoV-2?
Dhawan M; Saied AA; Mitra S; Alhumaydhi FA; Emran TB; Wilairatana P
Biomed Pharmacother; 2022 Oct; 154():113522. PubMed ID: 36030585
[TBL] [Abstract][Full Text] [Related]
16. Impact of SARS-CoV-2 Spike Mutations on Its Activation by TMPRSS2 and the Alternative TMPRSS13 Protease.
Stevaert A; Van Berwaer R; Mestdagh C; Vandeput J; Vanstreels E; Raeymaekers V; Laporte M; Naesens L
mBio; 2022 Aug; 13(4):e0137622. PubMed ID: 35913162
[TBL] [Abstract][Full Text] [Related]
17. The evolution of the spike protein and hACE2 interface of SARS-CoV-2 omicron variants determined by hydrogen bond formation.
Yang YY; Tseng YJ
Brief Funct Genomics; 2023 May; 22(3):291-301. PubMed ID: 36723978
[TBL] [Abstract][Full Text] [Related]
18. Origin, virological features, immune evasion and intervention of SARS-CoV-2 Omicron sublineages.
Xia S; Wang L; Zhu Y; Lu L; Jiang S
Signal Transduct Target Ther; 2022 Jul; 7(1):241. PubMed ID: 35853878
[TBL] [Abstract][Full Text] [Related]
19. A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent neutralization against Omicron and other SARS-CoV-2 variants.
Zhang J; Han ZB; Liang Y; Zhang XF; Jin YQ; Du LF; Shao S; Wang H; Hou JW; Xu K; Lei W; Lei ZH; Liu ZM; Zhang J; Hou YN; Liu N; Shen FJ; Wu JJ; Zheng X; Li XY; Li X; Huang WJ; Wu GZ; Su JG; Li QM
Elife; 2022 Aug; 11():. PubMed ID: 36004719
[TBL] [Abstract][Full Text] [Related]
20. Structural Study of SARS-CoV-2 Antibodies Identifies a Broad-Spectrum Antibody That Neutralizes the Omicron Variant by Disassembling the Spike Trimer.
Zhan W; Tian X; Zhang X; Xing S; Song W; Liu Q; Hao A; Hu Y; Zhang M; Ying T; Chen Z; Lan F; Sun L
J Virol; 2022 Aug; 96(16):e0048022. PubMed ID: 35924918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
